ONCC Certification Test Results Are Announced

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 1
Volume 11
Issue 1

PITTSBURGH-The Oncology Nursing Certification Corporation (ONCC) has announced the results of certification tests taken September 22, 2001. In a news release, the ONCC said that 154 registered nurses have earned their Advanced Oncology Certified Nurse (AOCN) credential. Of the 233 nurses who took the test, 66% earned a passing score, including 123 newly certified AOCNs and 31 renewals.

PITTSBURGH—The Oncology Nursing Certification Corporation (ONCC) has announced the results of certification tests taken September 22, 2001. In a news release, the ONCC said that 154 registered nurses have earned their Advanced Oncology Certified Nurse (AOCN) credential. Of the 233 nurses who took the test, 66% earned a passing score, including 123 newly certified AOCNs and 31 renewals.

Of nearly 3,000 nurses who took the Oncology Certified Nurse (OCN) test, 2,503 (85%) passed, including 1,409 who were newly certified and 1,094 who renewed their credential.

More than 300 registered nurses took the Certified Pediatric Oncology Nurse (CPON) examination, and 244 (77%) passed, 150 who were newly certified and 94 who renewed their CPON certification.

Articles in this issue
ODAC Sends Mixed Message on New Gliadel Wafer Indication
ONCC Certification Test Results Are Announced
Rituximab Ups Survival in Aggressive and Indolent NHL
Topotecan Used in Aggressive Front-Line Therapy for SCLC
Depsipeptide Shows Activity in T-Cell Lymphoma
FDG-PET Useful in Newly Diagnosed and Recurrent NSCLC
Adjuvant Anastrozole Superior to Tamoxifen in Huge ATAC Breast Cancer Trial
ODAC Backs Adding HER-2 DNA Test to Herceptin Package Insert
FDA and VA Plan Joint AIDS Study
Breast Conservation Increases With On-Site Radiation Unit
Washington State Hikes Cigarette Tax
Moffitt’s Diet Guidelines for Immunocompromised Patients
AMA Approves New CPT Code for Serum HER-2 Test
NCI Formalizes Role of Advocates
Better Prognosis for Outer Quadrant Breast Cancers
Recent Videos
3 experts in this video
3 experts in this video
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
The 2 main pafolacianine components, a folate analog and a dye, are commonly used in other medical applications.
Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.
Vinay K. Puduvalli, MD, is featured in this series.
Related Content
Active Monitoring Noninferior to Standard Surgery, RT in Low-risk DCIS

Active Monitoring Noninferior to Standard Surgery, RT in Low-risk DCIS

Gina Mauro
December 12th 2024
Article

Active monitoring had similar rates of invasive cancer in the ipsilateral breast as guideline concordant care for the low-risk DCIS population.

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

Ensuring Holistic, Individualized Transitions of Care for Cancer Survivors

Andrew M. Evens, DO, MBA, MSc
December 9th 2024
Podcast

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

Management and Prevention of AEs Associated With Ponatinib Improved

Management and Prevention of AEs Associated With Ponatinib Improved

Jonah Feldman
December 12th 2024
Article
A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

Kelley A. Rone, DNP, RN, AGNP-c
December 2nd 2024
Podcast

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Positive Safety Data Enforces Elacestrant as Treatment Option in HER2– Breast Cancer

Positive Safety Data Enforces Elacestrant as Treatment Option in HER2– Breast Cancer

Gina Mauro
December 12th 2024
Article
Early Breast Cancer Treatment Post the CDK4/6 Inhibitor Ribociclib’s FDA Approval

Early Breast Cancer Treatment Post the CDK4/6 Inhibitor Ribociclib’s FDA Approval

Darlene Dobkowski, MA
December 12th 2024
Article

During an FDA Special Session, field experts talked about the NATALEE trial and further information gathering on adjuvant ribociclib in breast cancer.